Drugs that contain Diazepam
1. Valtoco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265402 | NEURELIS INC | Absorption enhancers for drug administration |
May, 2025
(1 year, 5 months from now) | |
| US9642913 | NEURELIS INC | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
May, 2025
(1 year, 5 months from now) | |
| US8927497 | NEURELIS INC | Absorption enhancers for intranasal administration |
Jul, 2025
(1 year, 7 months from now) | |
| US8895546 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(5 years from now) | |
| US11241414 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(5 years from now) | |
| US11793786 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jan 10, 2027 |
| New Product (NP) | Jan 10, 2023 |
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older
Dosage: SPRAY;NASAL
More Information on Dosage
VALTOCO family patents
